Matches in SemOpenAlex for { <https://semopenalex.org/work/W2786100538> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2786100538 abstract "IL-2 was the first approved cancer immunotherapy and is still recognized for its durable responses. While IL-2 does mobilize relevant antitumor immune cells such as CD8+ T effector and activated NK cells, its utility is limited by parallel expansion of Treg cells and by dose-limiting toxicities. IL-2 Receptor alpha chain binding by IL-2 may be important in driving Treg expansion and some adverse side effects. Over the last decade, there have been approaches at modifying IL-2 structure-function or selecting antibodies that bind IL-2 and bias its activation of preferential cell types. One candidate (pegylated IL-2, NKTR-214) has moved into clinical development. XOMA mAb19 is a fully human monoclonal antibody to IL-2 that selectively compromises binding to IL-2R alpha chains, but not beta-gamma chains, thus potentially expanding IL-2’s antitumor therapeutic index. mAb19 binding characteristics and efficacy in a mouse Lewis Lung Carcinoma model were described at SITC 2016. In the current studies, a CT26 mouse colon carcinoma model was utilized to assess antitumor efficacy and tolerability of combined mAb19 + low-dose IL-2 dosing and to compare such with standard high-dose IL-2 regimens. The CT26 study results presented here demonstrate that mAb19 and IL-2 coadministration potentiates IL-2’s antitumor activity, expands CD8+ T effector and activated NK cells but not Treg cells, and is well tolerated. Specifically, treatment of tumor-bearing mice with about 1 mg/kg mAb19 plus about 0.1 mg/kg IL-2 yielded significant antitumor efficacy, which was at least as substantial as high-dose (e.g. 5 mg/kg) IL-2 regimens wherein significant body weight loss and ~10% mortality were observed. Notably, the mAb19 + IL-2 regimen had no dose-limiting toxicity. Moreover, the magnitude of antitumor response of the combination mAb19+IL2 was superior to that reported for NKTR-214 in the same model (AACR 2015). Preclinical development continues, including assessment for enhanced efficacy with checkpoint inhibitor(s). Citation Format: Kirk Johnson, Ou Li, Xiaohe Liu, Lucia Beviglia. Potentiation of IL-2’s antitumor efficacy without compromised tolerability by a novel human antibody [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B118." @default.
- W2786100538 created "2018-02-23" @default.
- W2786100538 creator A5031672257 @default.
- W2786100538 creator A5051543327 @default.
- W2786100538 creator A5053373754 @default.
- W2786100538 creator A5054071613 @default.
- W2786100538 date "2018-01-01" @default.
- W2786100538 modified "2023-09-26" @default.
- W2786100538 title "Abstract B118: Potentiation of IL-2’s antitumor efficacy without compromised tolerability by a novel human antibody" @default.
- W2786100538 doi "https://doi.org/10.1158/1535-7163.targ-17-b118" @default.
- W2786100538 hasPublicationYear "2018" @default.
- W2786100538 type Work @default.
- W2786100538 sameAs 2786100538 @default.
- W2786100538 citedByCount "0" @default.
- W2786100538 crossrefType "proceedings-article" @default.
- W2786100538 hasAuthorship W2786100538A5031672257 @default.
- W2786100538 hasAuthorship W2786100538A5051543327 @default.
- W2786100538 hasAuthorship W2786100538A5053373754 @default.
- W2786100538 hasAuthorship W2786100538A5054071613 @default.
- W2786100538 hasConcept C154317977 @default.
- W2786100538 hasConcept C159654299 @default.
- W2786100538 hasConcept C167672396 @default.
- W2786100538 hasConcept C185592680 @default.
- W2786100538 hasConcept C197934379 @default.
- W2786100538 hasConcept C202751555 @default.
- W2786100538 hasConcept C203014093 @default.
- W2786100538 hasConcept C2776090121 @default.
- W2786100538 hasConcept C2777701055 @default.
- W2786100538 hasConcept C2778375690 @default.
- W2786100538 hasConcept C2780674031 @default.
- W2786100538 hasConcept C2908885563 @default.
- W2786100538 hasConcept C502942594 @default.
- W2786100538 hasConcept C51785407 @default.
- W2786100538 hasConcept C542903549 @default.
- W2786100538 hasConcept C55493867 @default.
- W2786100538 hasConcept C71924100 @default.
- W2786100538 hasConcept C8891405 @default.
- W2786100538 hasConcept C98274493 @default.
- W2786100538 hasConceptScore W2786100538C154317977 @default.
- W2786100538 hasConceptScore W2786100538C159654299 @default.
- W2786100538 hasConceptScore W2786100538C167672396 @default.
- W2786100538 hasConceptScore W2786100538C185592680 @default.
- W2786100538 hasConceptScore W2786100538C197934379 @default.
- W2786100538 hasConceptScore W2786100538C202751555 @default.
- W2786100538 hasConceptScore W2786100538C203014093 @default.
- W2786100538 hasConceptScore W2786100538C2776090121 @default.
- W2786100538 hasConceptScore W2786100538C2777701055 @default.
- W2786100538 hasConceptScore W2786100538C2778375690 @default.
- W2786100538 hasConceptScore W2786100538C2780674031 @default.
- W2786100538 hasConceptScore W2786100538C2908885563 @default.
- W2786100538 hasConceptScore W2786100538C502942594 @default.
- W2786100538 hasConceptScore W2786100538C51785407 @default.
- W2786100538 hasConceptScore W2786100538C542903549 @default.
- W2786100538 hasConceptScore W2786100538C55493867 @default.
- W2786100538 hasConceptScore W2786100538C71924100 @default.
- W2786100538 hasConceptScore W2786100538C8891405 @default.
- W2786100538 hasConceptScore W2786100538C98274493 @default.
- W2786100538 hasLocation W27861005381 @default.
- W2786100538 hasOpenAccess W2786100538 @default.
- W2786100538 hasPrimaryLocation W27861005381 @default.
- W2786100538 hasRelatedWork W122948020 @default.
- W2786100538 hasRelatedWork W2064581203 @default.
- W2786100538 hasRelatedWork W2068913713 @default.
- W2786100538 hasRelatedWork W2085926838 @default.
- W2786100538 hasRelatedWork W2137450012 @default.
- W2786100538 hasRelatedWork W2153976491 @default.
- W2786100538 hasRelatedWork W2159214533 @default.
- W2786100538 hasRelatedWork W2205240900 @default.
- W2786100538 hasRelatedWork W2269860277 @default.
- W2786100538 hasRelatedWork W2317505050 @default.
- W2786100538 hasRelatedWork W2406825971 @default.
- W2786100538 hasRelatedWork W2477517254 @default.
- W2786100538 hasRelatedWork W2598942678 @default.
- W2786100538 hasRelatedWork W2738234259 @default.
- W2786100538 hasRelatedWork W3082961689 @default.
- W2786100538 hasRelatedWork W3098725826 @default.
- W2786100538 hasRelatedWork W3104437666 @default.
- W2786100538 hasRelatedWork W3111773541 @default.
- W2786100538 hasRelatedWork W3180985880 @default.
- W2786100538 hasRelatedWork W3214353368 @default.
- W2786100538 isParatext "false" @default.
- W2786100538 isRetracted "false" @default.
- W2786100538 magId "2786100538" @default.
- W2786100538 workType "article" @default.